Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025

Intra-Cellular Therapies, Inc. (ITCI) has emerged as one of the most promising psychedelic stocks to watch in 2025, with a robust pipeline of non-hallucinogenic psychedelic compounds and a strong focus on mental health treatment. As the psychedelic therapy market gains traction, ITCI's advanced drug development efforts position it for long-term growth and success.

ITCI's pipeline includes CAPLYTA (lumateperone), a non-hallucinogenic psychedelic compound that has shown positive results in treating major depressive disorder (MDD) and bipolar disorder with anxious distress and mixed features. In a pre-specified patient population in Study 403, CAPLYTA demonstrated antidepressant effects in patients with anxious distress and mixed features, further strengthening its potential as a broad treatment for MDD and other mood disorders (Source: GlobeNewswire, Dec. 5, 2023).



Another promising compound in ITCI's pipeline is ITI-1549, a novel non-hallucinogenic psychedelic for the treatment of neuropsychiatric disorders. Preclinical data on ITI-1549 presented at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting showed that it exhibits high affinity binding to 5-HT2a receptors and acts as an agonist at these receptors, favoring postsynaptic signaling within the beta-arrestin pathway. This suggests that ITI-1549 could have therapeutic potential without the hallucinogenic side effects associated with traditional psychedelics (Source: GlobeNewswire, Dec. 5, 2023).

ITCI's focus on non-hallucinogenic psychedelics allows the company to explore this psychoactive drug class in neuropsychiatric conditions without the liabilities of known psychedelics, such as induction of hallucinations and risks for cardiac valvular pathologies. This positions ITCI to capitalize on the growing interest in psychedelic therapies while mitigating potential risks and side effects.



Investors should also consider ITCI's strong quantitative momentum, as rated by Validea's Quantitative Momentum Investor model based on the published strategy of Wesley Gray. This model looks for stocks with strong and consistent intermediate-term relative performance, indicating that ITCI has shown promising momentum in the market (Source: Validea, Mar. 2, 2025).

In conclusion, Intra-Cellular Therapies, Inc. (ITCI) stands out as one of the best psychedelic stocks to buy in 2025 due to its advanced pipeline of non-hallucinogenic psychedelic compounds, strong preclinical data, experienced team, and promising quantitative momentum. As the psychedelic therapy market gains traction, ITCI's focus on mental health treatment and innovative drug development positions it for long-term growth and success. Investors should closely monitor ITCI's progress in clinical trials and regulatory filings to stay informed about potential breakthroughs and setbacks.